2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10264S
    Edoxaban-d6
    		Inhibitor 99.6%
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.
    Edoxaban-d<sub>6</sub>
  • HY-50903R
    Rivaroxaban (Standard)
    		Inhibitor
    Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban (Standard)
  • HY-76971
    Dechloro Rivaroxaban
    		Inhibitor 99.68%
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively.
    Dechloro Rivaroxaban
  • HY-50667R
    Apixaban (Standard)
    		Inhibitor
    Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban (Standard)
  • HY-50667S
    Apixaban-13C,d3
    		Inhibitor 99.53%
    Apixaban-13C,d3 (BMS-562247-01-13C,d3) is a deuterium and 13C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
    Apixaban-<sup>13</sup>C,d<sub>3</sub>
  • HY-76948
    5-R-Rivaroxaban
    		Inhibitor 99.97%
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban
  • HY-P6023A
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
    		Chemical 99.20%
    D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
  • HY-10267
    Eribaxaban
    		Inhibitor 98.52%
    Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces thrombus formation.
    Eribaxaban
  • HY-150224
    GalNAc unconjugated/naked Fitusiran sodium
    		Inhibitor 98.12%
    GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    GalNAc unconjugated/naked Fitusiran sodium
  • HY-50667S1
    Apixaban-d3
    		Inhibitor 99.9%
    Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667). Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Kis of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban-d<sub>3</sub>
  • HY-10264A
    Edoxaban tosylate
    		Inhibitor 99.97%
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate
  • HY-76835
    5-Chlorothiophene-2-carboxylic acid
    		99.86%
    5-Chlorothiophene-2-carboxylic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    5-Chlorothiophene-2-carboxylic acid
  • HY-14853
    Darexaban
    		Inhibitor 98.05%
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.
    Darexaban
  • HY-P3126
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride
    		98.68%
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate.
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride
  • HY-134685
    Edoxaban impurity 6
    		Inhibitor 98.30%
    Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
    Edoxaban impurity 6
  • HY-10268R
    Betrixaban (Standard)
    		Inhibitor
    Betrixaban (Standard) is the analytical standard of Betrixaban. This product is intended for research and analytical applications. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect.
    Betrixaban (Standard)
  • HY-10264R
    Edoxaban (Standard)
    		Inhibitor
    Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
    Edoxaban (Standard)
  • HY-172316
    BAY 3389934
    		Inhibitor
    BAY 3389934 is a selective dual inhibitor of factor IIa and factor Xa, with an IC50 of 4.9 nM for factor IIa and an IC50 of 0.66 nM for factor Xa. BAY 3389934 directly inhibits the activities of factor IIa and factor Xa and regulates the common coagulation pathway. BAY 3389934 exhibits anticoagulant and organ-protective effects. BAY 3389934 can be used in the research of sepsis and coagulopathy.
    BAY 3389934
  • HY-10268A
    Betrixaban maleate
    		Inhibitor 99.78%
    Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect.
    Betrixaban maleate
  • HY-10724
    Fidexaban
    		Inhibitor 99.62%
    Fidexaban is a Factor Xa inhibitor and can be used in research of cardiovascular disease.
    Fidexaban
Cat. No. Product Name / Synonyms Application Reactivity